Ann: MedAdvisor FY19 Annual Report & Appendix 4E, page-3

  1. 4,558 Posts.
    lightbulb Created with Sketch. 1993
    The underlying reason for the increased loss was due to the approx $4m spent on integration and capacity to be rolled out into international markets (see increase in development costs). That's half the total loss of $8m for the year.

    Now I don't know if that development is completed or not but if it is then our cost base will scale back.

    25% increase in sales isn't too shabby. If we can manage the same again then that's an additional $2m in revenue and with a profit margin of 88% there is very little additional cost of sales.

    Concerning is that there is $4m in the bank and $4m in expected outlays this quarter. There will be $2m in revenues to come in of course.

    Does anyone know if there is a R&D rebate due?

    The company will need cash from somewhere soon. Another raise perhaps?
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
7.8¢
Change
-0.002(2.50%)
Mkt cap ! $48.73M
Open High Low Value Volume
8.0¢ 8.0¢ 7.8¢ $15.10K 193.2K

Buyers (Bids)

No. Vol. Price($)
3 25695 7.8¢
 

Sellers (Offers)

Price($) Vol. No.
8.0¢ 45937 1
View Market Depth
Last trade - 10.45am 18/06/2025 (20 minute delay) ?
MDR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.